2nd Mitochondria-Targeted Drug Development Summit

We are happy to announce that the Mitochondria-Targeted Drug Development Summit, focused on the pursuit for novel effective therapies for mitochondrial disorders/dysfunction, return for its 2nd edition.

Incorporating insights from leading academics and pioneering biotech, this forum will specifically focus on targeting mitochondrial dysfunction to develop therapies for chronic diseases caused by mitochondrial DNA mutation/nuclear DNA mutations, muscle dystrophy diseases/muscle loss, metabolic disorders, neurodegenerative disease, and conditions linked to oxidative damage.

From basic research to the clinic, this year’s meeting will examine novel preclinical animal modelling solutions specifically targeting mitochondria, deliver an update on the current leading clinical trials showcasing mitochondrial transfer, mutations, metabolism, quality control, biogenesis, and peroxidation/ oxidation, along with dedicated sessions on the significance on informatics and data sharing for precision medicine.

Join 80+ leading experts as they navigate common challenges and opportunities for treating unmet medical needs caused by mitochondrial dysfunction. Mitobridge/Astellas, Minovia Therapeutics, Abliva, GenSight Biologics, Stealth Biotherapeutics and many more will unite drive to better understand how to create effective and scalable mitochondrial therapies.

Brochure https://go.evvnt.com/927944-0?pid=176 
Tickets https://go.evvnt.com/927944-3?pid=176 

Prices:
Industry Pricing: Conference + 2 Workshops USD 4197.00,
Industry Pricing: Conference + 1 Workshop USD 3598.00,
Industry Pricing: Conference Only USD 2999.00,
Academic Pricing: Conference + 2 Workshops USD 3597.00,
Academic Pricing: Conference + 1 Workshop USD 3098.00,
Academic Pricing: Conference Only USD 2599.00,
Solution Providers: Conference + 2 Workshops USD 4997.00,
Solution Providers: Conference + 1 Workshop USD 4298.00,
Solution Providers: Conference Only USD 3599.00

Speakers: Selvaraj Nataraja, Senior Director, Translational Research, Mitobridge/Astellas, Natalie Yivgi-Ohana, Co-Founder & Chief Executive Officer, Minovia, Magali Taiel, Chief Medical Officer, GenSight Biologics, Alexander Schueller, Founder & Chief Executive Officer, Cellvie, Victor Shengkan Jin, Founder, Mito BioPharma, Joseph Sarret, President & Chief Executive Officer, CohBar, Jonah Sinick, Chief Executive Officer, Equator Therapeutics, Rishi Rakhit Director, Translational Medicine, Mitokinin, Gino Cortopassi, Chief Executive Officer, Ixchel Pharma, Matthew Klein, Chief Development Officer, PTC Therapeutics, Ben Albensi, Chief Scientific Officer, Mitrix Bio, Reenie McCarthy, Chief Executive Officer, Stealth Biotherapeutics, Pénélope Andreu, Mitochondrial & Muscle Biology, Amazentis/Vandria, Christopher Missling, President & Chief Executive Officer, Anavex Life Sciences Corp, Bärbel (Barb) Roher, Co-Founder & Chief Scientific Officer, MitoChem Therapeutics, Gregory Flesher, President & Chief Executive Officer, Reneo Pharma, Ellen Donnelly, Chief Executive Officer, Abliva, Michael Fossel, President & Founder, Telocyte, Maxim Skulachev, Chief Scientific Officer, Mitotech, Daria Mochly-Rosen, The George D Professor, Translational Medicine, Professor, Dept Chemical & Systems Biology/Founder & Co-director, Stanford University, School of Medicine/SPARK, Stanford, David Marcinek, Professor of Radiology, Adjunct of Bioengineering and Laboratory Medicine and Pathology, University of Washington Medical School, Hazel Szeto, Co-Founder & Director/Scientific Founder, Improving Global Health, Inc./Stealth BioTherapeutics, Keshav Singh, Joy & Bill Harbert Endowed Chair & Professor/Scientific Founder & Chief Scientific Officer, University of Alabama, Birmingham/Yuva Biosciences, Dan DiPietro, Founding Partner, Aceras Bio, David Schaaf, Vice President, US Medical Affairs, Senior Medical Officer, Zogenix

Date and Time: Starts: Tue, Feb 22, 22 ( 9:00 AM) and Ends: Thu, Feb 24, 22 ( 5:00 PM)